These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 26982179)

  • 1. Pharmacokinetic and pharmacodynamic responses in adult patients with Chagas disease treated with a new formulation of benznidazole.
    Fernández ML; Marson ME; Ramirez JC; Mastrantonio G; Schijman AG; Altcheh J; Riarte AR; Bournissen FG
    Mem Inst Oswaldo Cruz; 2016 Mar; 111(3):218-21. PubMed ID: 26982179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and Tissue Distribution of Benznidazole after Oral Administration in Mice.
    Perin L; Moreira da Silva R; Fonseca KD; Cardoso JM; Mathias FA; Reis LE; Molina I; Correa-Oliveira R; Vieira PM; Carneiro CM
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous liposomal benznidazole as trypanocidal agent: increasing drug delivery to liver is not enough.
    Morilla MJ; Montanari JA; Prieto MJ; Lopez MO; Petray PB; Romero EL
    Int J Pharm; 2004 Jul; 278(2):311-8. PubMed ID: 15196636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of benznidazole in adult patients with Chagas disease.
    Soy D; Aldasoro E; Guerrero L; Posada E; Serret N; Mejía T; Urbina JA; Gascón J
    Antimicrob Agents Chemother; 2015; 59(6):3342-9. PubMed ID: 25824212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elucidating the impact of low doses of nano-formulated benznidazole in acute experimental Chagas disease.
    Rial MS; Scalise ML; Arrúa EC; Esteva MI; Salomon CJ; Fichera LE
    PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006119. PubMed ID: 29267280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Scheme of Intermittent Benznidazole Administration in Patients Chronically Infected with Trypanosoma cruzi: a Pilot Short-Term Follow-Up Study with Adult Patients.
    Álvarez MG; Hernández Y; Bertocchi G; Fernández M; Lococo B; Ramírez JC; Cura C; Albizu CL; Schijman A; Abril M; Sosa-Estani S; Viotti R
    Antimicrob Agents Chemother; 2016 Feb; 60(2):833-7. PubMed ID: 26596935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Technological innovation strategies for the specific treatment of Chagas disease based on Benznidazole.
    Ferraz LRM; Alves AÉG; Nascimento DDSDS; Amariz IAE; Ferreira AS; Costa SPM; Rolim LA; Lima ÁAN; Rolim Neto PJ
    Acta Trop; 2018 Sep; 185():127-132. PubMed ID: 29452113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetic study of benznidazole in pediatric Chagas disease suggests efficacy despite lower plasma concentrations than in adults.
    Altcheh J; Moscatelli G; Mastrantonio G; Moroni S; Giglio N; Marson ME; Ballering G; Bisio M; Koren G; García-Bournissen F
    PLoS Negl Trop Dis; 2014 May; 8(5):e2907. PubMed ID: 24853169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety assessment of different dosage of benznidazol for the treatment of Chagas disease in chronic phase in adults (MULTIBENZ study): study protocol for a multicenter randomized Phase II non-inferiority clinical trial.
    Molina-Morant D; Fernández ML; Bosch-Nicolau P; Sulleiro E; Bangher M; Salvador F; Sanchez-Montalva A; Ribeiro ALP; de Paula AMB; Eloi S; Correa-Oliveira R; Villar JC; Sosa-Estani S; Molina I
    Trials; 2020 Apr; 21(1):328. PubMed ID: 32293523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanocarrier-enhanced intracellular delivery of benznidazole for treatment of Trypanosoma cruzi infection.
    Li X; Yi S; Scariot DB; Martinez SJ; Falk BA; Olson CL; Romano PS; Scott EA; Engman DM
    JCI Insight; 2021 May; 6(9):. PubMed ID: 33986194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seronegative conversion after incomplete benznidazole treatment in chronic Chagas disease.
    Alvarez MG; Vigliano C; Lococo B; Petti M; Bertocchi G; Viotti R
    Trans R Soc Trop Med Hyg; 2012 Oct; 106(10):636-8. PubMed ID: 22898619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose of benznidazole promotes therapeutic cure in experimental chronic Chagas' disease with absence of parasitism in blood, heart and colon.
    Perin L; Fonseca KDS; de Carvalho TV; Carvalho LM; Madeira JV; Medeiros LDF; Molina I; Correa-Oliveira R; Carneiro CM; Vieira PMA
    Exp Parasitol; 2020 Mar; 210():107834. PubMed ID: 31978394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First report of a family outbreak of Chagas disease in French Guiana and posttreatment follow-up.
    Blanchet D; Brenière SF; Schijman AG; Bisio M; Simon S; Véron V; Mayence C; Demar-Pierre M; Djossou F; Aznar C
    Infect Genet Evol; 2014 Dec; 28():245-50. PubMed ID: 25448161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of benznidazole treatment combined with nifurtimox, posaconazole or AmBisome® in mice infected with Trypanosoma cruzi strains.
    Cencig S; Coltel N; Truyens C; Carlier Y
    Int J Antimicrob Agents; 2012 Dec; 40(6):527-32. PubMed ID: 23063742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Success of benznidazole chemotherapy in chronic Trypanosoma cruzi-infected patients with a sustained negative PCR result.
    Murcia L; Carrilero B; Ferrer F; Roig M; Franco F; Segovia M
    Eur J Clin Microbiol Infect Dis; 2016 Nov; 35(11):1819-1827. PubMed ID: 27488437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial.
    Torrico F; Gascon J; Ortiz L; Alonso-Vega C; Pinazo MJ; Schijman A; Almeida IC; Alves F; Strub-Wourgaft N; Ribeiro I;
    Lancet Infect Dis; 2018 Apr; 18(4):419-430. PubMed ID: 29352704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of novel benznidazole solutions during the experimental infection with Trypanosoma cruzi.
    Manarin R; Lamas MC; Bottasso E; Serra E; Revelli S; Salomón CJ
    Parasitol Int; 2013 Feb; 62(1):79-81. PubMed ID: 22975280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial of posaconazole and benznidazole for chronic Chagas' disease.
    Molina I; Gómez i Prat J; Salvador F; Treviño B; Sulleiro E; Serre N; Pou D; Roure S; Cabezos J; Valerio L; Blanco-Grau A; Sánchez-Montalvá A; Vidal X; Pahissa A
    N Engl J Med; 2014 May; 370(20):1899-908. PubMed ID: 24827034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benznidazole vs benznidazole in multilamellar liposomes: how different they interact with blood components?
    Morilla MJ; Prieto MJ; Romero EL
    Mem Inst Oswaldo Cruz; 2005 Apr; 100(2):213-9. PubMed ID: 16021311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experimental combination therapy using low doses of benznidazole and allopurinol in mouse models of Trypanosoma cruzi chronic infection.
    Rial MS; Scalise ML; López Alarcón M; Esteva MI; Búa J; Benatar AF; Prado NG; Riarte AR; Fichera LE
    Parasitology; 2019 Mar; 146(3):305-313. PubMed ID: 30301480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.